Fortis Healthcare Ltd. · NSE:FORTIS
Fortis Healthcare — Q4 FY25 Earnings Presentation
49 slides from Fortis Healthcare's earnings presentation, May 20, 2025
Slide 1: Cover letter to stock exchanges under Regulation 30
Fortis Healthcare Limited Tower-A, Unitech Business Park, Block-F, South City 1, Sector – 41, Gurgaon, Haryana – 122 001 (India) Tel : 0124 492 1033 Fax : 0124 492 1041 Emergency : 105010 Email : secretarial@fortishealthcare.com Website : www.fortishealthcare.com May 20, 2025 FHL/SEC/2025-26 The Nat
Slide 2: Fortis Healthcare announces Q4 FY25 and FY25 Financial Results
Press Release May 20, 2025 Fortis Healthcare announces Q4 FY25 and FY25 Financial Results Hospital Business Revenues up 14.2% for the quarter; 14.8% for the year Hospital business Op.EBITDA margins at 21.9% for the quarter; 20.5% for the year Board recommends dividend of INR 1 per share (10% of Face
Slide 3: Press Release: Key Financial Highlights
Press Release May 20, 2025 % Change % Change Hospital Business (INR Cr) Q4FY24^ Q4FY25^ FY24 FY25 YoY YoY Revenue 1,490 1,701 14.2% 5,686 6,528 14.8% Operating EBITDA 333 372 11.7% 1,058 1,339 26.6% Operating EBITDA Margin 22.4% 21.9% 18.6% 20.5% ^ Comprises adjustments of amounts related to Expecte
Slide 4: Hospital Business Highlights
Press Release May 20, 2025 HOSPITAL BUSINESS HIGHLIGHTS KPIs Q4FY24 Q4FY25 FY24 FY25 Occupancy 66% 69% 65% 69% ARPOB (INR/Cr p.a.) 2.32 2.51 2.22 2.42 ALOS (Days) 4.41 4.22 4.28 4.19 • Revenue growth for FY25 was led by an increase in ARPOB of 9% and a growth of approx. 5% in occupied beds compared
Slide 5: Diagnostics Highlights and CEO Commentary
Press Release May 20, 2025 • Continuing with its network expansion strategy, primarily the addition of new customer touch points (CTPs); total CTPs reached to approx. 4,171 as on 31st March 2025 compared to approx. 3,976 as on 31st March 2024. • In FY25, Agilus conducted ~39.2 Mn tests versus ~38.8
Slide 6: Fortis Healthcare Limited – Q4 FY25 and FY25
FORTIS HEALTHCARE LIMITED EARNINGS PRESENTATION – Q4 FY25 and FY25 May 20, 2025 1
Slide 7: Disclaimer
DISCLAIMER This presentation may not be copied, published, distributed or transmitted. The presentation has been prepared solely by the company. Any reference in this presentation to “Fortis Healthcare Limited” shall mean, collectively, the Company and its subsidiaries. This presentation has been pr
Slide 8: About Fortis Healthcare
About Fortis Healthcare National Capital Region ➢ FMRI, Gurugram 27 Healthcare Facilities* ➢ FEHI, New Delhi ➢ Shalimar Bagh 1,896 ➢ Noida ➢ Vasant Kunj (O&M) ~4,750 Operational Beds^ ➢ Faridabad ➢ Manesar, Gurugram Punjab ➢ La Femme GK ➢ Mohali ➢ Def Col 7,500+ Doctors ➢ Ludhiana 773 ➢ C-DOC (O&M)
Slide 9: Agenda
AGENDA 1. Clinical Excellence at Fortis 2. Performance Highlights • Earnings and Financial Summary – Q4FY25 and FY25 3. Performance Review - Hospital Business • Beds Expansion Update • ESG Highlights 4. Performance Review - Diagnostics Business 5. Appendix 4
Slide 10: Clinical Excellence at Fortis
CLINICAL EXCELLENCE AT FORTIS KEY HIGHLIGHTS 5
Slide 11: Clinical Excellence: FY25 Key Procedures
CLINICAL EXCELLENCE FY25 Performance – Key Procedures 67,400+ 30,500+ ~6,200 Cardiac Procedures1 Joint Replacements and Robotic Surgeries3 Other Ortho Procedures 1,000+ ~9,200 12,600+ Transplants2 Neuro and Spine Radiation Therapy Surgeries Patients Note: FY25 witnessed YoY growth across key procedu
Slide 12: Clinical Excellence
CLINICAL EXCELLENCE Q4 FY25 • Fortis Escorts, Okhla Road, New Delhi, performed India’s first kidney auto-transplant on a 6-year-old boy from Uzbekistan with bilateral Wilms tumour—a rare kidney cancer—enabling precise tumour removal while minimizing the risk of cancer cell spread. Q1–Q3 FY25 • Forti
Slide 13: Augmenting Medical Programs
AUGMENTING MEDICAL PROGRAMS ➢ Fortis Hospital, Gurugram, ➢ Fortis Hospital, Gurugram, introduced launched North & Central South Asia’s first Gamma Knife Espirit India’s first MR LINAC, to treat radiosurgery equipment for neurosurgical tumors with precision treatment to attain precision to target bra
Slide 14: Performance Highlights Q4FY25 and FY25
Q4FY25 and FY25 PERFORMANCE HIGHLIGHTS 9
Slide 15: Business Performance
BUSINESS PERFORMANCE Consolidated (INR Cr) 7,783 % Revenue Growth YoY 6,893 1,588 (20.4%) 6,298 1,268 (18.4%) 1,101 (17.5%) 809 633 9.5 645 12.9 FY23 FY24 FY25 Revenue Op. EBITDA Reported PAT (XX%) Op. EBITDA margin Hospital Business (INR Cr) 6,528 5,686 % Revenue 5,107 1,339 Growth YoY (20.5%) 1,05
Slide 16: Q4FY25 Snapshot
Q4FY25 SNAPSHOT Consolidated Revenue Consolidated Op EBITDA Consolidated PBT1 2,007 Crores 435 Crores 290 Crores (21.7% Margin) 12.4% 14.3% 8.2% Consolidated PAT1 Net Debt / (Cash)3 Net Debt to EBITDA2,3 242 Crores 1,694 Crores 0.93x vs 0.17x 20.8% 1. Excluding exceptional items 2. Basis Q4FY25 annu
Slide 17: FY25 Snapshot
FY25 SNAPSHOT Consolidated Revenue Consolidated Op EBITDA Consolidated PBT1 7,783 Crores 1,588 Crores 1,096 Crores (20.4% Margin) 12.9% 25.3% 30.2% Consolidated PAT1 Net Debt / (Cash)3 Net Debt to EBITDA2,3 899 Crores 1,694 Crores 0.93x vs 0.17x 42.8% Board recommends dividend of INR 1 per share (10
Slide 18: Key Updates
Key Updates Q4 FY25 ‘Fortis’ brand and trademarks Acquisition of Shrimann Hospital Mar’25/ Apr’25 : The company successfully Feb’25: The company signed definitive agreements for the acquired the ‘Fortis’ brand and trademarks acquisition of 228-bedded Shrimann Superspecialty through a public auction
Slide 19: Q4FY25 Snapshot
Q4FY25 SNAPSHOT ➢ Hospital business revenues grew 14.2% to INR 1,701 Cr versus INR 1,490 Cr in Q4FY24 ➢ Hospital Business Operating EBITDA stood at INR 372 Cr, up 11.7%; while operating margin was at 21.9%* versus 22.4%* in Q4FY24 ➢ Q4FY25 hospital business ARPOB was at INR 2.51 Cr per annum vs INR
Slide 20: FY25 Snapshot
FY25 SNAPSHOT ➢ Hospital business revenue at INR 6,528 Cr versus INR 5,686 Cr in FY24, a growth of 14.8% ➢ Hospital business Operating EBITDA at INR 1,339 Cr versus INR 1,058 Cr in FY24, a growth of 26.6%; Margin at 20.5% vs 18.6% in FY24 ➢ FY25 hospital business ARPOB at INR 2.42 Cr vs INR 2.22 Cr
Slide 21: Consolidated Earnings Summary – Q4FY25
CONSOLIDATED EARNINGS SUMMARY – Q4FY25 All figures in INR Cr Revenue Op EBITDA & Margin 2,007 435 1,928 380 375 1,786 21.7% 21.3% 19.4% Q4FY24 Q3FY25 Q4FY25 Q4FY24 Q3FY25 Q4FY25 Up 12.4% Up 14.3% PBT before Exceptional Items PAT* 290 268 231 242 256 200 Q4FY24 Q3FY25 Q4FY25 Q4FY24 Q3FY25 Q4FY25 Up 8
Slide 22: Consolidated Earnings Summary – FY25
CONSOLIDATED EARNINGS SUMMARY – FY25 All figures in INR Cr. Revenue Op EBITDA & Margin 7,783 1,588 1,268 6,893 20.4% 18.4% FY24 FY25 FY24 FY25 Up 12.9% Up 25.3% PBT before Exceptional Items PAT* 1,096 899 842 629 FY24 FY25 FY24 FY25 Up 30.2% Up 42.8% * FY25 PAT excludes exceptional net loss of INR 8
Slide 23: Consolidated Earnings Summary
CONSOLIDATED EARNINGS SUMMARY All figures in INR Cr Consolidated Revenue 1,988 2,007 1,928 1,859 1,786 Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Op EBITDA Margin Op EBITDA PBT (before Exceptional items) 21.9% 21.7% 21.3% 19.4% 18.4% 435 435 380 375 343 321 268 290 256 230 Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q4FY25
Slide 24: Hospital Business Highlights Q4FY25
Q4FY25 HOSPITAL BUSINESS HIGHLIGHTS Key Performance Indicators • Occupancy was at 69%, compared to 66% in Q4FY24. Overall Occupancy Occupied beds increased to 2,855 compared to 2,706 in Q4FY24, a 69% 67% 66% growth of 5.5%. • Revenue from focus specialties comprising Oncology, Neurosciences, Cardiac
Slide 25: Hospital Business Highlights FY25
FY25 HOSPITAL BUSINESS HIGHLIGHTS Key Performance Indicators Overall Occupancy • Occupancy was at 69%, compared to 65% in FY24. 69% Occupied beds increased to 2,838 compared to 2,700 in FY24, a 65% growth of 5.1%. • Revenue from focus specialties comprising Oncology, Neurosciences, Cardiac Sciences,
Slide 26: Diagnostic Business Highlights Q4FY25
Q4FY25 DIAGNOSTIC BUSINESS HIGHLIGHTS • Agilus reported gross revenue of INR 348.5 Cr in Q4FY25 as compared to INR 338.4 Cr in Q4FY24. • Operating EBITDA stood at INR 62.6 Cr in Q4FY25 versus INR 47.2 Cr in Q4FY24 (18.0% versus 14.0% EBITDA margin basis gross revenues). • Operating EBITDA before one
Slide 27: Diagnostic Business Highlights FY25
FY25 DIAGNOSTIC BUSINESS HIGHLIGHTS • Agilus reported gross revenue of INR 1,406.7 Cr in FY25 as compared to INR 1,372.0 Cr in FY24. • Operating EBITDA (basis gross revenues) stood at INR 248.6 Cr in FY25 versus INR 209.4 Cr in FY24 (17.7% versus 15.3% EBITDA margin basis gross revenues). • Operatin
Slide 28: Operating Performance: Hospital Business
OPERATING PERFORMANCE HOSPITAL BUSINESS Hospital Business Particulars (INR Cr) Q4FY24* Q3FY25 Q4FY25* FY24 FY25 Operating Revenue 1,490 1,623 1,701 5,686 6,528 Revenue Growth vs LY 10.3% 16.8% 14.2% 11.3% 14.8% Reported EBITDA 339 340 384 1,090 1,388 EBITDA growth vs LY 47.5% 34.0% 13.2% 18.3% 27.3%
Slide 29: Operating Performance: Diagnostic Business
OPERATING PERFORMANCE DIAGNOSTIC BUSINESS Diagnostic Business Particulars (INR Cr) Q4FY24 Q3FY25 Q4FY25 FY24 FY25 Operating Revenue 338 342 348 1,372 1,407 Revenue Growth vs LY 1.9% 3.5% 3.0% 1.8% 2.5% Reported EBITDA 52 56 71 229 274 EBITDA growth vs LY -5.7% 51.1% 37.9% -12.8% 19.8% Margin 15.2% 1
Slide 30: Balance Sheet (Consolidated)
BALANCE SHEET (CONSOLIDATED) March 31, 2025 Balance Sheet (INR Cr) March 31, 2024 Dec 31, 2024 Mar 31, 2025 Shareholder’s Equity 8,556 8,984 9,169 Debt 859 2,341 2,196 Lease Liabilities (Ind AS 116)* 297 268 280 Total Capital Employed 9,711 11,593 11,645 Net Fixed Assets (including intangibles & CWI
Slide 31: Performance Review: Hospitals Business
PERFORMANCE REVIEW HOSPITALS BUSINESS 26
Slide 32: Specialty Mix
SPECIALTY MIX FY24 FY25 Other Operating Other Operating Revenue, 1.7% Revenue, 1.9% OPD, 13.8% OPD, 13.4% Cardiac, Cardiac, 17.3% 17.8% Other IPD, Other IPD, Ortho, 8.6% 16.4% Ortho, 8.7% 16.6% Renal, 7.3% Renal, 6.9% Gynae, 3.6% Gynae, 3.3% Neuro, 8.8% Pulmo, 2.9% Neuro, 8.5% Pulmo, 2.9% Onco, 14.3
Slide 33: Payor Mix
PAYOR MIX FY24 FY25 TPAs, 35.3% TPAs, 36.2% Cash : Cash : Domestic, Domestic, 34.3% 36.1% Pvt Corps, Pvt Corps, 0.8% 1.0% International , Govt & International , 7.8% Govt & PSUs, 8.7% 8.0% PSUs, 8.7% ECHS, 7.4% CGHS, 4.1% ECHS, 7.0% CGHS, 4.5% 28
Slide 34: Hospital Business Performance – Q4FY25 & FY25
HOSPITAL BUSINESS PERFORMANCE – Q4FY25 & FY25 Key healthcare facilities continue to witness a YoY upward momentum in revenues Revenue Q4FY24 Q4FY25 262 207 203 All figures in INR Cr. 178 172 133 135 146 129 140 135 115 125 117 83 95 52 60 66 53 FMRI Mohali Shalimar Bagh BG Road Noida Mulund FEHI Ana
Slide 35: Hospital Business Performance – FY25
HOSPITAL BUSINESS PERFORMANCE – FY25 Key hospitals witnessed healthy ARPOB and Occupancy growth ARPOB (Rs Cr per annum) FY24 FY25 4.21 3.81 3.12 3.18 2.86 3.01 2.80 3.01 2.42 2.16 2.04 2.20 2.14 2.38 1.67 1.67 1.64 1.33 1.46 1.55 FMRI Mohali Shalimar Bagh BG Road Noida Mulund FEHI Anandpur Faridabad
Slide 36: Hospital Margin Matrix
HOSPITAL MARGIN MATRIX EBITDA No of Facilities Revenue Contribution Operational beds ARPOB (INR Cr) Occupancy >20% 10 73.2% 2,611 2.67 72% 15% - 20% 4 8.0% 487 1.49 75% FY25* 10% - 15% 2 8.8% 346 2.55 70% <10% 5^ 8.7% 652 1.80 52% ^ Note: <10% EBITDA Margin facilities include Ludhiana 2 (commissione
Slide 37: Beds Expansion Update
BEDS EXPANSION UPDATE 32
Slide 38: Beds Expansion Plan
Beds Expansion Plan No. of Operational Beds Planned capacity addition of ~2000 beds* from FY26 to FY29 New Bed Addition Major addition at Major Major addition Manesar, FMRI, addition at at Mohali Major addition Noida, BG Road, ASR and SB at ANP and FBD and Jalandhar1 Jalandhar1 Major addition at Man
Slide 39: Key Ongoing Expansion Projects
Key Ongoing Expansion Projects Manesar Facility (~300 Beds)* – Phase 1 Operationalized (~90 Beds) Faridabad New Tower (50 Beds) – Expected operationalization H1FY26 Expected Phase 2 Capacity Addition: H1FY26 Noida New Tower (~150 Beds) – ~60 Beds operationalized: Q1FY26 FMRI New Beds (20 Beds throug
Slide 40: ESG Highlights
ESG HIGHLIGHTS 35
Slide 41: ESG Highlights
ESG HIGHLIGHTS Environment Energy Water Bio-Medical Waste Stewardship Reduced per occupied bed energy 98% deployment of water metering Monitoring month-wise baseline for bio- consumption in FY25 by 6.0% infrastructure across hospitals enhances medical waste for all units, across all 5 our water gove
Slide 42: Performance Review: Diagnostics Business
PERFORMANCE REVIEW DIAGNOSTICS BUSINESS 37
Slide 43: Diagnostics Business – Q4FY25 and FY25
DIAGNOSTICS BUSINESS – Q4FY25 and FY25 Q4FY25 • During Q4FY25, Agilus conducted 9.59 Mn tests, versus 9.19 Mn in Q4FY24. • Agilus added 140+* Customer touchpoints to its network in Q4FY25. • Agilus’ B2C: B2B revenue mix stood at 51:49 in the quarter, similar to Q4FY24. FY25 • During FY25, Agilus con
Slide 44: Yearly Revenue Mix
YEARLY REVENUE MIX Geographic mix Product Mix Segment Mix International 3% Wellness 11% B2C, North 52% FY25 South 31% 31% B2B, Routine Specialised 55% 48% 34% East 13% West 21% International 3% Wellness 10% North 33% B2C, FY24 South 51% 29% B2B, Routine Specialised 49% 54% 36% East West 14% 21% 39
Slide 45: Key Performance Metrics
KEY PERFORMANCE METRICS Test (mn) Avg. Realization per test (INR) No of Patients (mn) Avg. Realization per patient (INR) 10.5 368 370 4.60 900 4.40 869 890 880 10 365 360 860 357 357 4.20 9.5 353 350 854 840 845 846 4.00 820 9 346 340 822 3.80 800 9.5 9.2 9.6 10.4 9.6 9.6 4.0 3.9 4.0 4.4 4.0 3.9 8.5
Slide 46: Appendix
| x la Z uu Oo. oO. <x
Slide 47: Group Consolidated P&L – Q4FY25
GROUP CONSOLIDATED P&L – Q4FY25 Particulars ( INR Cr) Q4FY24 Q3FY25 Q4FY25 Revenue from operations 1,785.9 1,928.3 2,007.2 Other income 9.8 20.9 19.8 Total income 1,795.7 1,949.2 2,027.0 Expenses 1,404.9 1,553.1 1,571.7 EBITDA* 390.8 396.0 455.3 Margin 21.9% 20.5% 22.7% Finance costs 34.7 45.2 67.6
Slide 48: Group Consolidated P&L – FY25
GROUP CONSOLIDATED P&L – FY25 Particulars (INR Cr) FY24 FY25 Revenue from operations 6,892.9 7,782.8 Other income 38.3 66.9 Total income 6,931.2 7,849.7 Expenses 5,625.3 6,194.8 EBITDA* 1,305.9 1,654.9 Margin 18.9% 21.3% Finance costs 131.0 184.4 Depreciation and amortisation expense 342.5 385.6 PBT
Slide 49: Thank You
THANK YOU 44